Efficacy and safety of hydroquinone-containing topical regimens versus active topical treatments without hydroquinone for facial melasma: a systematic review of randomized clinical trials published since 2020

This systematic review protocol describes the methods for evaluating the efficacy and safety of hydroquinone-containing topical regimens compared with active topical treatments without hydroquinone in adults with facial melasma. The review will include randomized clinical trials whose first full publication of results appeared from 1 January 2020 to the date of the final search. Hydroquinone monotherapy, hydroquinone-based triple combination therapy, and other hydroquinone-containing combinations will be assessed separately against specific topical comparators. Eligible comparisons will involve exclusively topical treatments, without concomitant procedures or systemic therapies targeting melasma. Searches will be conducted in PubMed, Embase, CENTRAL, Scopus, and LILACS, supplemented by trial registries, reference checking, and citation searching. The primary efficacy outcome will be the change in melasma severity measured using MASI or mMASI, with the scales assessed separately and the primary assessment conducted at the time point closest to 12 weeks within an 8- to 16-week window. Primary safety outcomes will include adverse events and treatment discontinuation due to adverse events. Secondary outcomes will include instrumental pigmentation measurements, clinician and patient assessments, quality of life, and recurrence. Risk of bias will be assessed using the Cochrane RoB 2 tool, and certainty of the evidence will be evaluated using GRADE. Findings will be presented through a structured narrative synthesis without meta-analysis, following the SWiM reporting guideline. The protocol was developed in accordance with PRISMA-P, and the completed review will be reported in accordance with PRISMA 2020.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-19
DOI
https://doi.org/10.5281/zenodo.24381942
Primary Topic
Dermatologic Treatments and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and safety of hydroquinone-containing topical regimens versus active topical treatments without hydroquinone for facial melasma: a systematic review of randomized clinical trials published since 2020

Juan Pablo Holguín-Carvajal, ARIANA ELIZABETH SALCEDO VASQUEZ, PAULA ANABEL GUERRERO VASQUEZ
Zenodo (CERN European Organization for Nuclear Research)
Dermatologic Treatments and Research
article

Efficacy and safety of hydroquinone-containing topical regimens versus active topical treatments without hydroquinone for facial melasma: a systematic review of randomized clinical trials published since 2020

Juan Pablo Holguín-Carvajal, ARIANA ELIZABETH SALCEDO VASQUEZ, PAULA ANABEL GUERRERO VASQUEZ
article en

Abstract

This systematic review protocol describes the methods for evaluating the efficacy and safety of hydroquinone-containing topical regimens compared with active topical treatments without hydroquinone in adults with facial melasma. The review will include randomized clinical trials whose first full publication of results appeared from 1 January 2020 to the date of the final search. Hydroquinone monotherapy, hydroquinone-based triple combination therapy, and other hydroquinone-containing combinations will be assessed separately against specific topical comparators. Eligible comparisons will involve exclusively topical treatments, without concomitant procedures or systemic therapies targeting melasma. Searches will be conducted in PubMed, Embase, CENTRAL, Scopus, and LILACS, supplemented by trial registries, reference checking, and citation searching. The primary efficacy outcome will be the change in melasma severity measured using MASI or mMASI, with the scales assessed separately and the primary assessment conducted at the time point closest to 12 weeks within an 8- to 16-week window. Primary safety outcomes will include adverse events and treatment discontinuation due to adverse events. Secondary outcomes will include instrumental pigmentation measurements, clinician and patient assessments, quality of life, and recurrence. Risk of bias will be assessed using the Cochrane RoB 2 tool, and certainty of the evidence will be evaluated using GRADE. Findings will be presented through a structured narrative synthesis without meta-analysis, following the SWiM reporting guideline. The protocol was developed in accordance with PRISMA-P, and the completed review will be reported in accordance with PRISMA 2020.

Zenodo (CERN European Organization for Nuclear Research)
Universidad del Azuay (EC)
Dermatologic Treatments and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon